Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression DATA from E11.5 pancreatic buds treated with I-BET151 or JQ1 for 24h

ABSTRACT: Expression DATA from E11.5 pancreatic buds treated with I-BET151 or JQ1 for 24h

PROVIDER: PRJNA432198 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Expression DATA from E11.5 pancreatic buds treated with I-BET151 or JQ1 for 24h

Project description:Bromodomain and Extra-terminal (BET) proteins are epigenetic readers that interact with acetylated lysines of histone tails. Recent studies have demonstrated their role in cancer progression, as they recruit key components of the transcriptional machinery to modulate gene expression. However, their role during embryonic development of the pancreas has never been studied. Using mouse embryonic pancreatic explants and human IPSC, we show that inhibition of BET proteins with either I-BET151 or JQ1 dramatically enhances the number of neurogenin3 (NEUROG3) endocrine progenitors, leading to an increased number of endocrine cells in the pancreatic explants. Despite inducing several β cell markers, BETi also strongly down-regulated Ins1 expression in developed explants and adult β cells. However, removal of BETi from explants prior to β cell development, as NEUROG3 expression peaks, further led to enhanced β cell development with higher expression of insulin and maturation markers UCN3 and MAFA. Altogether, these results show that BET proteins play a major role in the pancreas endocrine differentiation. Furthermore, they highlight the potential use of BETi to improve β cell replacement therapies.

2020-01-01 | GSE109858 | GEO

RNA sequencing analysis of wild-type and ITF2357 or I-BET151 or JQ1 treated mouse pancreatic cancer KPC cells

Project description:The ITF2357, I-BET151 and JQ1 promote antigen presentation and sensitize pancreatic cancer to T cell cytotoxicity, in combination with Immune checkpoint blockage therapy suppress tumor cell growth

2025-10-25 | GSE216552 | GEO

Transcriptomic analysis of T84 colon carcinoma cell line treated with trametinib, JQ1 or their combination

Project description:T84 cells were treated with DMSO, 30nM trametinib (MEKi), 1µM JQ1 (BRD4i) or the combination of trametinib and JQ1 (combo) for 24h.

2018-10-23 | GSE118548 | GEO

Effect of a 24h corticosterone treatment on differentiated C2C12 myotubes

Project description:Long term glucocorticoïds treatment, e.g. corticosterone, induces insulin resistance in vivo and in vitro. In vivo insulin resistance can trigger pancreatic beta cells adaptation in order to maintain glycemia. In particular, we observed that beta-cell mass adaptation can occur via beta-cell proliferation or via beta-cell neogenesis (de novo beta-cell production). Further, we demonstrated that beta-cell neogenesis was not a direct effect of GC, but rather due to the presence of pro-neogenic factors in the serum of GC-treated mice, suggesting a communication in-between insulin resistant tissues and the pancreas (Courty et al., Diabetes, 2019). Hence, the present work aims to decipher the role of the skeletal muscle in pancreatic adaptation in response to insulin resistance. We used an in vitro modeling in-between C2C12 differentiated myotubes treated for 24h with corticosterone (10-7M) or the same volume of solvant ethanol (VEH). Conditioned medium from corticosterone treated cells was tested on pancreatic buds E11.5 and proven to enhance beta-cell and other pro-endocrine lineage cellular differentiation in comparison to VEH conditioned medium. Subsequently, we analyzed the transcriptome of the C2C12 myotubes (n=3 per condition) using RNAsequencing (Illumina, NOVAseq 6000, 150bp paired-end sequencing). We found an enrichement for genes coding for secreted proteins in the CORT-treated myotubes. We narrowed down to 4 myokines candidates and validated the pro-neogenic potential of the candidate myokines using pancreatic buds E11.5 treated with recombinant proteins.

2025-09-10 | GSE261984 | GEO

RNA sequencing analysis of wild-type and ITF2357 or I-BET151 or JQ1 treated mouse pancreatic cancer KPC cells

Project description:RNA sequencing analysis of wild-type and ITF2357 or I-BET151 or JQ1 treated mouse pancreatic cancer KPC cells

| PRJNA894206 | ENA

Thermal proteome profiling of JQ1

Project description:Goal of this experiment was the identification of proteins affected in their thermal stability by JQ1.

2018-05-02 | PXD008638 | Pride

BMDM treated with I-BET151 and sitmulated with IgG immune complex

Project description:Bone marrow derived macrophages were cultured and stimulated with I-BET151 or DMSO control, and stimulated with Ovalbumin-IgG immune complex or Ovalbumin control.

2022-05-02 | GSE200033 | GEO

BMDC treated with I-BET151 and sitmulated with IgG immune complex

Project description:Bone marrow derived dendritic cells were cultured and stimulated with I-BET151 or DMSO control, and stimulated with Ovalbumin-IgG immune complex or Ovalbumin control.

2022-05-02 | GSE200226 | GEO

2 Dimensional Thermal proteome profiling of JQ1

Project description:Goal of this experiment was the identification of proteins affected dose dependently in their thermal stability by JQ1.

2018-05-02 | PXD008626 | Pride

Multiplexed proteome dynamics profiling of JQ1-PROTAC

Project description:Goal of this experiment was the differentiation of direct targets of induced degradation of the JQ1-PROTAC from downstream regulatory effects.

2018-05-02 | PXD008637 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data